Top

Pathology & Oncology Research

Published in:

01-01-2016 | Letter to the Editor

Frameshift Mutations of CAB39L, an Activator of LKB1 Tumor Suppressor, in Gastric and Colorectal Cancers

Authors: Mi Ryoung Choi, Chang Hyeok An, Nam Jin Yoo, Sug Hyung Lee

Published in: Pathology & Oncology Research | Issue 1/2016

Excerpt

To the Editor: …

Alessi DR, Sakamoto K, Bayascas JR (2006) LKB1-dependent signaling pathways. Transcription 4:29–33

Hemminki A, Tomlinson I, Markie D, Järvinen H, Sistonen P, Björkqvist AM, Knuutila S, Salovaara R, Bodmer W, Shibata D, de la Chapelle A, Aaltonen LA (1997) Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet 15:87–90CrossRefPubMed

Sanchez-Cespedes M (2007) A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 26:7825–7832CrossRefPubMed

Mehellou Y, Alessi DR, Macartney TJ, Szklarz M, Knapp S, Elkins JM (2013) Structural insights into the activation of MST3 by MO25. Biochem Biophys Res Commun 431:604–609PubMedCentralCrossRefPubMed

Ling P, Lu TJ, Yuan CJ, Lai MD (2008) Biosignaling of mammalian Ste20-related kinases. Cell Signal 20:1237–1247CrossRefPubMed

Imai K (2008) Yamamoto H (2008) carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29:673–680CrossRefPubMed

Yoo NJ, Kim HR, Kim YR, An CH (2012) Lee SH (2012) Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 60:943–952CrossRefPubMed

Je EM, Kim MR, Min KO, Yoo NJ, Lee SH (2012) Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Int J Cancer 131:E1044–E1047CrossRefPubMed

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW (2013) Cancer genome landscapes. Science 339:1546–1558PubMedCentralCrossRefPubMed

10.

Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12:323–334CrossRefPubMed

Title: Frameshift Mutations of CAB39L, an Activator of LKB1 Tumor Suppressor, in Gastric and Colorectal Cancers
Authors: Mi Ryoung Choi
Chang Hyeok An
Nam Jin Yoo
Sug Hyung Lee
Publication date: 01-01-2016
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 1/2016
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-015-9973-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2016

The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis

Pattern of Tumour Spread of Common Primary Tumours as Seen on Magnetic Resonance Imaging

Evaluation of Histological and non-Invasive Methods for the Detection of Liver Fibrosis: The Values of Histological and Digital Morphometric Analysis, Liver Stiffness Measurement and APRI Score

The Assessment of the Magnitude of Frontal Plane Postural Changes in Breast Cancer Patients After Breast-Conserving Therapy or Mastectomy – Follow-up Results 1 Year After the Surgical Procedure

Expression of LC3, LAMP2, KEAP1 and NRF2 in Salivary Adenoid Cystic Carcinoma

Leukemia Relapse-Associated Mutation of NT5C2 Gene is Rare in de Novo Acute Leukemias and Solid Tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer